An experimental Zika vaccine developed by US scientists has been found in two early clinical trials to be safe and promising in preventing infection by the deadly virus. The findings, published in the journal Lancet, showed that it induced an immune response in healthy adults. The investigational vaccine, developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, includes a small, circular piece of DNA called a plasmid. Scientists inserted genes into the plasmid that encode two proteins found on the surface of the Zika virus. The researchers found that when
91 – 22 – 2490 0302.